Donna Neuberg

Donna Neuberg

Harvard University

H-index: 164

North America-United States

About Donna Neuberg

Donna Neuberg, With an exceptional h-index of 164 and a recent h-index of 95 (since 2020), a distinguished researcher at Harvard University,

His recent articles reflect a diverse array of research interests and contributions to the field:

Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination

Corrigendium: Effects of RAS on the genesis of embryonal rhabdomyosarcoma

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP

Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential

Integrative genotyping of cancer and immune phenotypes by long-read sequencing

Donna Neuberg Information

University

Position

Dana-Farber Cancer Institute

Citations(all)

105979

Citations(since 2020)

42567

Cited By

80024

hIndex(all)

164

hIndex(since 2020)

95

i10Index(all)

613

i10Index(since 2020)

437

Email

University Profile Page

Google Scholar

Top articles of Donna Neuberg

Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination

Nature Nanotechnology

2024/3/15

Corrigendium: Effects of RAS on the genesis of embryonal rhabdomyosarcoma

Genes & Development

2024/3/1

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP

Leukemia & Lymphoma

2024/2/21

Robert Redd
Robert Redd

H-Index: 21

Donna Neuberg
Donna Neuberg

H-Index: 84

Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD

Bone Marrow Transplantation

2024/2/21

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Leukemia

2024/2/20

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Blood Advances

2024/2/13

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential

Nature Communications

2024/1/4

Integrative genotyping of cancer and immune phenotypes by long-read sequencing

Nature Communications

2024/1/2

Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival

Blood Advances

2024/4/16

The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities

Transplantation and Cellular Therapy

2024/4/6

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

Leukemia

2024/3/27

Systematic Prediction of Minor Histocompatibility Antigens to Inform GvHD Outcomes after Allogeneic Stem Cell Transplantation

Blood

2023/11/28

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

Blood Advances

2023/9/26

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Blood

2023/4/13

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Blood

2023/11/28

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged≥ 60 years

Blood Advances

2023/9/26

Organ Involvement in BPDCN Is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival

Blood

2023/11/28

Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders

Pediatric Blood & Cancer

2023/9

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Blood

2023/11/28

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood

2023/4/13

See List of Professors in Donna Neuberg University(Harvard University)